(Q29398488)

English

Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients withKRASwild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial

scientific article (publication date: 15 October 2014)

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25319061%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25319061%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

phase I clinical trial

0 references

phase II clinical trial

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25319061%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Josep Tabernero Caturla

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25319061%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

E Élez

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25319061%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

I Kocáková

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25319061%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

T Höhler

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25319061%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

U M Martens

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25319061%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

C Bokemeyer

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25319061%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

E Van Cutsem

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25319061%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

B Melichar

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25319061%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

T Csőszi

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25319061%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

E Topuzov

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25319061%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

R Orlova

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25319061%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

S Tjulandin

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25319061%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

F Rivera

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25319061%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

J Straub

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25319061%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

R Bruns

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25319061%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

S Quaratino

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25319061%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

15 October 2014

2 references

DOI.org query endpoint

https://doi.org/10.1093%2FANNONC%2FMDU474

14 April 2017

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25319061%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Annals of Oncology

2 references

DOI.org query endpoint

https://doi.org/10.1093%2FANNONC%2FMDU474

14 April 2017

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25319061%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

26

2 references

DOI.org query endpoint

https://doi.org/10.1093%2FANNONC%2FMDU474

14 April 2017

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25319061%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1

2 references

DOI.org query endpoint

https://doi.org/10.1093%2FANNONC%2FMDU474

14 April 2017

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25319061%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

132-140

2 references

DOI.org query endpoint

https://doi.org/10.1093%2FANNONC%2FMDU474

14 April 2017

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25319061%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU474

21 January 2018

Integrins as therapeutic targets.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU474

21 January 2018

Alpha-v integrins as therapeutic targets in oncology.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU474

21 January 2018

Matched rabbit monoclonal antibodies against αv-series integrins reveal a novel αvβ3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU474

21 January 2018

Multiplicity of fibronectin-binding alpha V integrin receptors in colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU474

21 January 2018

Safety, tolerability, and pharmacokinetics of the novel αv-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU474

21 January 2018

A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting αv integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU474

21 January 2018

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU474

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU474

21 January 2018

Colorectal cancer progression: integrin alphavbeta6 and the epithelial-mesenchymal transition (EMT).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU474

21 January 2018

TGF-β activation and function in immunity

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU474

21 January 2018

Identifiers

10.1093/ANNONC/MDU474

3 references

DOI.org query endpoint

https://doi.org/10.1093%2FANNONC%2FMDU474

14 April 2017

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25319061%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25319061%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q29398488&oldid=1749474598"